Abstract:OBJECTIVE:To assess the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in the treatment of Chinese patients with active ankylosing spondylitis.METHODS:This multicenter, randomized, double-blind, positive-controlled phase III clinical trial was conducted in 19 centers across China. Chinese adults with active ankylosing spondylitis despite being treated with non-steroidal anti-inflammatory drugs for ≥ 4 weeks were randomized in a 1:1 ratio to subcutaneously receive 40 mg of TQ-Z2301 or adalimumab every other week for 24 weeks. The primary endpoint was the percentage of patients who achieved at least 20% improvement according to the Assessment of Spondyloarthritis International Society criteria (ASAS20) at week 24. The equivalence was established if the 90% CI for RR of ASAS20 between two groups at week 24 fell within (0.80, 1.25). Secondary endpoints included efficacy measures of disease activity, spinal mobility, physical function and quality of life, immunogenicity, and pharmacokinetic parameters. Safety analysis was done for all patients who received at least one study drug.RESULTS:A total of 380 patients were enrolled in the study between September 2018 and October 2019, including 188 in the TQ-Z2301 group and 192 in the adalimumab group. In the full analysis population, the ASAS20 response rate at week 24 was 86.70% in the TQ-Z2301 group, and 80.73% in the adalimumab group, the RR of ASAS20 for TQ-Z2301 versus adalimumab was 1.074, 90% CI (0.997, 1.157), fell within the predefined equivalence boundary (0.80, 1.25). Except for the SF-36 at week 12, there was no statistical difference between the two groups for all the secondary endpoints (P>0.05). The incidence of adverse events group was 82.45% in the TQ-Z2301, and 83.85% in the adalimumab group, the safety profile of the two groups was similar. The profiles of immunogenicity and pharmacokinetics were also similar between the two groups.CONCLUSION:TQ-Z2301 is equivalent to adalimumab for the treatment of Chinese patients with active ankylosing spondylitis. The safety, immunogenicity, and pharmacokinetic characteristics of both drugs are similar.TRIAL REGISTRATION:The study (CTR20181863) was registered in the Chinese Clinical Trial Registry on 19 October 2018. Key Points • TQ-Z2301 showed the equivalence of efficacy compared with the reference adalimumab for the treatment of Chinese patients with active ankylosing spondylitis. • The safety, immunogenicity, and pharmacokinetics profiles of TQZ-2301 were similar to those of the reference adalimumab.

Targeted therapies and conventional care for the treatment of ankylosing spondylitis in China: a cost-effectiveness analysis based on the network-meta analysis

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey

Comparison of the Efficacy and Safety of the Adalimumab Biosimilar TQ-Z2301 and Adalimumab for the Treatment of Chinese Patients with Active Ankylosing Spondylitis: a Multi-Center, Randomized, Double-Blind, Phase III Clinical Trial

Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis.

Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression

Evaluation of Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis Based on a Health Survey: Sub-Analysis of a Phase 3 Study

Cost-effectiveness of Anbainuo Plus Methotrexate Compared to Conventional Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients in China

Comparative efficacy, safety and cost of oral Chinese patent medicines for rheumatoid arthritis: a Bayesian network meta-analysis

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

Current health resources required for the management of ankylosing spondylitis in developing areas of China

Pharmacoeconomics Evaluation of Infliximab in the Treatment of Ankylosing Spondylitis

The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada

Effects of traditional qigong exercise on ankylosing spondylitis: a protocol for systematic reviews and meta-analysis

Efficacy and Safety of a Novel Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ : Fc Fusion Protein in Chinese Patients with Active Ankylosing Spondylitis: Results of a Randomized, Double-Blind,multicenter Trial

Clinical Research of 45 Ankylosing Spondylitis Treated with Integrated Chinese and Western Medicine